|Bid||11.16 x 1000|
|Ask||11.29 x 1000|
|Day's Range||11.00 - 11.33|
|52 Week Range||4.20 - 13.70|
|PE Ratio (TTM)||39.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...
COLUMBIA, Md., Sept. 17, 2018-- Osiris Therapeutics, Inc., a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Dermagraft® (1) is a bioengineered human fibroblast-derived dermal substitute product that has been on the U.S. market for more than 15 years (2, 3). Grafix® is a cryopreserved placental tissue allograft that has been developed using a proprietary cryopreservation method. This method allows the retention of intact matrix, growth factors and cells native to placental tissue. Prior clinical studies have shown the safety and efficacy of both Grafix and Dermagraft when used in the treatment for chronic DFUs in their respective trials (4, 5). The study’s objective was to compare clinical outcomes and product cost between Grafix and Dermagraft as an adjunct to standard of care (SOC) in the treatment of chronic DFUs in a prospective, multicenter, single-blind study.
COLUMBIA, Md., Aug. 01, 2018-- Osiris Therapeutics, Inc., a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced ...
COLUMBIA, Md., July 11, 2018-- Osiris Therapeutics, Inc., a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation ...
SAN DIEGO, CA / ACCESSWIRE / November 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors who purchased NASDAQ: OSIR shares against Osiris Therapeutics, ...
A former chief financial officer of biotechnology company Osiris Therapeutics on Thursday pleaded guilty to making false statements to auditors to inflate the company's reported revenue. Philip Jacoby, 65, entered his plea before U.S. District Judge Denise Cote in in Manhattan, while Osiris separately agreed to pay $1.5 million to settle a related civil lawsuit by the U.S. Securities and Exchange Commission, court records showed. As part of the plea, Jacoby and prosecutors agreed that an appropriate sentence under federal guidelines would be four to 10 months in prison and a fine of up to $5 million.